

How to Deliver an Effective Research Presentation

Eugene S. Kim, MD
Associate Professor of Surgery & Pediatrics
Children's Hospital Los Angeles
USC Keck School of Medicine

October 20, 2018



Disclosures



• No disclosures

Outline



- Important factors for giving an effective presentation
- Examples of what is good and what is not so good
- Helpful tips and advice

Critical aspects of a presentation



- The content of what you say
- How you show it
- How you say it

Structure of presentation



- Background what's the problem
- Hypothesis how can we fix the problem
- Methods what techniques did you use
- Results
- Conclusions

Background



- What's the problem?
- How is the current question related to the problem?
- Assume your audience knows nothing about your topic
- Distill and be brief

Hypothesis



- Flows from the background
 - How will you address your problem?
 - What do you think will happen?

Methods



- Say what is needed
- Excessive detail will be distracting
- Numbers
- Statistical analyses
- Figures pictures

Results



- Clear figures with clear legends
- Clear stats
- Clear tables in large font
- Highlight interesting data
- Keep it simple

Conclusions



- Circle back to hypothesis
- Clear and simple points
- Future direction

Slide Content



- Font size, color
- Amount of content
- Level of detail
- Animation augment, not distract

THIS

IS

DISTRACTING

Presentation style



- Posture
- Eye contact
- Speaking vs reading
- Avoid the uuummmm
- Microphone etiquette

Posture



- Stand up tall
- Hands on the podium
 - Careful with gesticulations
- Don't move about

Eye contact



- Get your head up and out of the notes
- Look at your audience members
- Look back and forth at your data to keep them focused

• Engage!

Speak to your audience



- Do not read slides
- Deliver bullet points while you augment with your words

Pointer



- Do not follow words with laser pointer
- When using a pointer, use two hands
 - Move slowly and purposefully to show points of interest

Constraints



- Time
- Amount of information
- Complexity of information
- Attention span of audience
- Knowledge base of your audience

Time



- Be respectful of the time limit!
- Practice, practice, practice

Amount of information



- If short on time, cut the data
- Better to present less data clearly, than a lot of data poorly
- Distill, be concise, focus on the important points

Complexity of information



- Your job is to make it digestible
- Make every talk a lay talk
- Use figures and pictures

Attention span



- Keep an eye on your audience
- Make clear critical points take home messages
- Re-focus attention


Engaging audience



- Make them listen to you
 - Tell a story
- Inflection, timing
- Keep your audience happy

Practical exam





Unmatched cohort analysis



Demographics, Outcomes, and Adverse Events	Preimplementation (n = 93)	Postimplementation (n = 70)	P Value
Baseline demographics			
Male, No. (%)	51 (55)	33 (47)	.35
Diagnosis, No. (%)			
NEC	49/	36 (51)	.88
Gastroschisis		21 (30)	.74
Atresia		13 (19)	.38
Other		0 (0)	1.00
Gestational age, wka		33.5 (26, 36)	.66
Birth weight, g a		1786.5 (840, 2602)	.59
RSB percent estimated, No. (%)			
>40%		55 (79)	.58
20%-40%	,	(13)	1.00
<20%	K	5 (7)	.78
Outcomes			
Time to full feeds ^a	18	15 (10, 38)	.70
Time to start PO after reanastomosis ^{a,b}	10 (2	9.5 (6, 13)	.04
Days of PN ^a	64 (34, /10)	52 (29, 94)	.27
LOS after definitive surgery ^a	40 (22, 99)	38 (21, 63)	.52
Highest total bilirubin ^{a,b}	6.7 (2.6, 10)	3.9 (1.0, 6.1)	.0005
Total bilirubin at dischargea,b	2.1 (0.5, 4.1)	0.7 (0.4, 3.0)	.02
Percent time of hospital stay with elevated	50 (0, 91)	24 (0, 70)	.03
total bilirubin ^{a,b}			
Use of fish oil, No. (%) ^b	22 (24)	1 (1)	<.001
Use of phenobarbital, n (%) ^b	19 (20)	6 (9)	.05
Use of ursodeoxycholine, No. (%)	35 (38)	21 (30)	.32
In-hospital adverse events and breast milk use, No. (%)		
In-hospital mortality	3 (3)	0 (0)	.26
PNALD	54 (58)	32 (46)	.15
Postsurgical NEC	4 (4)	4 (6)	.73
CLABSI	23 (25)	16 (23)	.85
Predominant use of BM during	37 (40)	48 (69)	<.0001
advancement to 50% of goal ^b			

Standardization of feeding after surgery




Table 1.	Infant Enter	al Feeding G	uiden of	or Postabdomi	Intesting	gery.
----------	--------------	--------------	----------	---------------	-----------	-------

Patient Type and Feeding	11	Day		7 Day	rs
Residual small bowel ^a	>40% remaining continuity with		a in	<20% remaining sm continuity with co	
Patient weight, g	<1500	≥1500		<1500	≥1500
Initial enteral feeds ^b	12 mL/kg/d continuous feeds	12-24 mL/kg continuous bolus feeds	for tinuous OR d interstittent continuous feeds	1 mL every 3 hours for 7 days, then 12 mL/ kg/d continuous OR intermittent continuous feeds	12 mL/kg/d continuous feeds
Feeding increases	Increase by 12 mL/kg/d every 48 hours	Increase by 24 mL/kg/d every 24 hours	Increase by 12 mL/kg/d every 3 days	Increase by 12 mL/A days	cg/d every 7
Feeding intolerance ^c	Evaluate every 3 intolerance, hole hours and reasse	d feeds for 12	Evaluate every 3 hours. If intolerance, hold feeds for 12 hours and reassess.	Evaluate every 3 ho intolerance, hold f hours and reassess	eeds for 12

Feeding protocols in IF patients





Outcomes in IF patients




Diagnoses Associated with	stinal Fai	and SI owel Syndrome in Infants (N=272)
DIAGNOSIS	4	
Necrotizing enterocolitis		
Gastroschisis		
Intestinal atresia (large/small)	27	
Volvulus	1 (9)	
Long segment Hirschsprung disease	11 (4)	
Tufting or Microvillus inclusion	3 (1)	V
Other single diagnoses	14 (5)	
Unknown	1	
Multiple single diagnoses	77 (28)	


Pulmonary Barotrauma in Congenital Diaphragmatic Hernia: A Clinicopathological Correlation




By Yoshio Sakurai, Kenneth Azarow, Ernest Cutz, Antonio Megsineo, Richard Pearl, and Desmond Bohn Toronto, Ontari/ ig Injury in CDH Table 3. Cha Total No. of Characteristics Contralateral Occurrences (%)(%)of Lung Injury Hyaline membrane 62/68 (91 52/68 (1 **9**/68 (13) 1/68 (1) formation 9/68 (1/3) 44/68 (65) 10/68 (15) 25/68 (37) Pneumothorax 1/68 (1) 4/6(6)Intertitial fibrosis 3/68 (5) Parenchymai hemor-35/68 (50) 32/68 (46) 3/68 (4) rhage. 12/68 (18) 10/68 (15) 1/68 (1) 23/68 Bronchopneumonia









CC-10, SPC, and T1 α positive cells



Co-implantation of HIO and OU maintains differentiated epithelial cell development




Expanded periportal cells:




Pre-hepatocyte phenotype

Expanded cells are proliferating but HNF4α⁻



HNF4α: marker of hepatocyte differentiation•Negative expression suggests a HPC phenotype

PROM1 cells express epithelial and mesenchymal markers



Background

 Neuroblastoma represents ~15% of all pediatric cancer related deaths

• High-risk neuroble all rate: 40-50%

• ~80% of high-risk patter vill hitially achieve remission

• Most common cause of death from <u>relapse</u> and <u>metastatic</u> <u>disease</u>

Background

vival rate: 40-


• Neuroblastoma represents 15% of all pediatric cancer related deaths

High-risk ne50%


• 80% of high-risk patient will initially achieve remission

 Most common cause of death from <u>relapse</u> and metastatic disease

Implanted Prior to ARG1 Knockout



Methods



A Prospective Study of Expectant Observation as Primary Therapy for Neuroblastoma in Young Infants

A Children's Oncology Group Study

Jed G. Nuchtern, MD,* Wendy B. London, PhD,†|| Carol Patrick W. McGrady, MS,||¶ James D. Geiger, MD,# Diller, MD,†|| Mary Lou Schmidt, MD,**

John M. Seis, MD,†† Susar Cohn, Mary Lou Robert C. Shamberger, MD§

inter study including

- •Study design: Prospe Children's Oncology
- •Patient population < 6 per six all adrenal masses and no evidence of spreading beyon the rimary tumor
- •Methods: Parents chose observation or immediate surgical resection. Serial abdominal sonograms and urinary vanillylmandelic acid and homovanillic acid measurements were performed during a 90-week interval. Infants experiencing a 50% increase in the volume of the mass, urine catecholamine values, or an increase in the homovanillic acid to vanillylmandelic acid ratio greater than 2, were referred for surgical resection.

Necrotizing Enterocolitis

BETTINA BOHNHORST, N. CLAUS S. PETER, MD,

- J Pediatrics, 2003
- Single-center, retrospective cohort
- Advanced at 20cc/kg/day after 3 days of no portal venous gas on ultrasound



Necrotizing Enterocolitis-early refeeding

- 28 infants with Named are observation
- 19 infants with
- 2 recurrences in gro

 Tread in historical control
- Conclusions: Not significant difference but underpowered




Cronobacter sakazakii using V6-V8 primer

Sequence File: 7-16s-rRNA-FWD_R.seq 🛂.ab1 >7-16s-rRNA-FWD NNNNNNNNNCGCNNNN TCNN GCTTTGCTGACGAGTGGCGGACGGGTGA GTAATGTCTGGGAAACTGCC GCTAATACCGCATAACGTCGCAAGACCAA AGTGGGGGACCTTCGGGCCTCA CGACGATCCCTAG® CCAGACTCCTACGGGAGGCAGCA GTGGGGAATATTGCAC GAAGAAGGCCTTCGGGTTGTAAAGTAC TTTCAGCGAGGAGGAAGGG GCAGAAGAAGCACCGGCTAACTCCGT GCCAGCAGCCGCGGTAAT4 GCGCACGCAGGCGGTCTGTCAA GTCGGATGTGAAATC CAGGCTTGAGTCTCGTAGAGGGGGGGTAGAA TTCCAGGTGTAGCGGTGAAATGCGT iAAGGCGGCCCCCTGGACGAAGACTGACGC TCAGGTGCGAAAGCGTGGGGAGCA CGCCGTAAACGATGTCGACTTGGAGGTTG TGCCCTTGAGGCGTGGCTTCCGGAGCTAAC TAAGT CGCCTGGG AGTACGGCCGCAAGGTTAAAACTCAAAT GAATTGACGGGGGCCCGCACAAGCGGTGGA rgtggtt ATTCGATGCAACGCGAAGAACCTTACCTGGNCTTGACA TCCANNGAANNCNTGCAGANATGNNNNNNTd TTCGGNANTCTGANACAGNTGCTGCATGGCTGTCGTCAGCTCGTNTN NGAATGTGGNNNNTCCNNCANGAGCNNNNCNNNATCCTTNNTGCCAGCNNNTCATGNNNGNNNNNNAAGNNNNNNTGNCN **GGNNNNN**

	Description		Max score	Total score	Query cover	E value	Ident	Accession
[Cronobacter muvtiensii strain Jor149 168 ribosomal RNA n		1783	1783	89%	0.0	98%	FJ906912.1
[Cronobacter muytjensii strain E603; ATCC 51329 16S ribosomal	acter muytjensii strain E603	1779	1779	89%	0.0	98%	NR 044059.1
	Cronobacter muytjensii strain E456 16S ribosom		1779	1779	89%	0.0	98%	EF059837.1
	Cronobacter muytjensii strain E488 16S ribosomal RNA		1779	1779	89%	0.0	98%	EF059840.1
	Cronobacter muytjensii strain WJ1635 16S ribosomal RNA		1777	1777	89%	0.0	98%	KC818190.1
	Cronobacter muytjensii strain WJ1619 16S ribosom		1777	1777	89%	0.0	98%	KC818177.1
	Cronobacter muytjensii strain WJ1078 16S ribosomal RNA gene, pa		1777	1777	89%	0.0	98%	KC818149.1
	Cronobacter muytjensii strain ZJN392B3 16S ribosomal RNA gene partial segl		1777	1777	89%	0.0	98%	JX307659.1
	Cronobacter muytjensii partial 16S rRNA gene, isolate PHLTA-6		1777	1777	89%	0.0	98%	FN401338.1


FGF10 signals from mesenchymal cells to hepatic progenitor cells





- Mesenchymal cells express Fgf10
- Embryonic HPCs potentially express FGFR2b

Early ABx Protect Against Opportunistic Pathogens



Goals of Today's Session

In Pediatric Trace Pati S:

- Identification types
- Imaging and ma
- Indications for cerval color and radiographic imaging
- Screening for intra-abdominal injury, indications for imaging
- Identification of patients at risk for NAT

Goals of Today's Session

In Pediatric Trace Pati S:

- Identification Techniques types
- Imaging and ma
- Indications for cerval color and radiographic imaging
- Screening for intra-abdominal injury, indications for imaging
- Identification of patients at risk for NAT

The End



• Questions?





Email: eugeneskim@chla.usc.edu